Moderna COVID-19 vaccine phase III trial results published; it is 94.1% efficacious in preventing symptomatic COVID-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine – New England Journal of Medicine

Commentaries: Peer-reviewed report on Moderna COVID-19 vaccine publishes – NIH News Releases AND Peer-reviewed data show high protection for leading COVID vaccines – CIDRAP AND The Moderna Vaccine’s Antibodies May Not Last As Long As We Hoped – Forbes

Commentary on Twitter

In the phase 3 mRNA-1273 trial participants received 2 doses of vaccine or placebo 28 days apart. The mRNA-1273 vaccine showed 94.1% efficacy in preventing #SARSCoV2, including severe disease. #IDTwitter

— NEJM (@NEJM) December 30, 2020